 |
|
|
| |
Concordance Between SVR4, SVR12, and SVR24 in HCV-Infected Patients Who Received Fixed-Dose Combination Sofosbuvir/Velpatasvir in Phase 3 Clinical Trials
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
M. SULKOWSKI1, J. FELD2, N. REAU3, S. SCHERBAKOVSKY4, C. HERNANDEZ4, K. VANSTRAELEN4, K. HAMMOND4, B. KRETER4, V. SURI4, L. NI4, M. BOURLIERE5, A. MANGIA6
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Canada; 3Rush University Medical Center, Chicago, IL, USA; 4Gilead Sciences, Inc., Foster City, CA; 5Hôpital Saint Joseph, Marseilles, France; 6Fondazione "Casa Sollievo Della Sofferenza" IRCCS, San Giovanni Rotondo, Italy
|
| |
|
|
|
|
|
